Digitisation | December 08, 2021
Olympus lays out its plans for growth in the medical business
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Subscribe To Our Newsletter & Stay Updated
